• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Sheep Fibrinogen gamma prime (gamma' 408-427 specific), also called Peak 2 Fibrinogen Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS512221
Unit / Price
Scan QR to view Datasheet
  0.2 mg  /  $340 +1 FREE 8GB USB
anti-Fibrinogen gamma prime (gamma' 408-427 specific), also called Peak 2 Fibrinogen antibody
Product Name

Fibrinogen gamma prime (gamma' 408-427 specific), also called Peak 2 Fibrinogen, Polyclonal Antibody

Full Product Name

Sheep anti-Fibrinogen gamma prime (Fg-gamma'), Peroxidase Conjugated IgG

Product Synonym Names
Fibrinogen gamma prime (gamma' 408-427 specific), also called Peak 2 Fibrinogen, human
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Clonality
Polyclonal
Host
Sheep
Specificity
Prior to conjugation, this antibody was specific for gamma'- containing forms of fibrinogen (as demonstrated by immunoelectrophoresis and immunoblotting).
Purity/Purification
Peroxidase conjugated IgG.
Vial containing ml of whole IgG conjugated to horseradish peroxidase (HRP) through carbohydrate groups. Total protein is 0.2 mg.
Form/Format
IgG-HRP conjugate as a clear, slightly red-brown liquid.
Concentration
IgG-HRP concentration is mg/ml, determined by absorbance using an extinction coefficient (E1%280) of 14. (lot specific)
Immunogen
A synthetic peptide containing the sequence unique to the gamma' chain (VRPEHPAETEYDSLYPEDDL) conjugated to keyhole limpet hemocyanin carrier.
Buffer
A buffered stabilizer solution containing 50% (v/v) glycerol.
Preparation and Storage
Store between -10 and -20 degree C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use. Avoid exposure to sodium azide as this is an inhibitor of peroxidase activity.
Other Notes
Small volumes of anti-Fibrinogen gamma prime (gamma' 408-427 specific), also called Peak 2 Fibrinogen antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Human fibrinogen is a 340 kDa plasma protein produced in the liver. Plasma concentrations are typically 1.7 - 3.5 g/L (5-10 uM). The intact fibrinogen molecule consists of two identical subunits, each consisting of three non-identical polypeptide chains denoted as Aalpha, Bbeta and gamma. The letters A and B in the Aalpha and Bbeta chains designate, respectively, fibrinopeptide A (FpA, residues 1-16), and fibrinopeptide B (FpB, residues 1-14), which are cleaved by thrombin upon conversion of fibrinogen to fibrin. The fibrin monomers polymerize in a half-overlap fashion to form insoluble fibrin fibrils. The polymerised fibrin is subsequently stabilized by activated Factor XIII that forms amide linkages between gamma chains and, to a lesser extent, alpha chains of the fibrin molecules. Proteolysis of fibrinogen by plasmin initially liberates C-terminal residues from the Aalpha chain to produce fragment X (intact D-E-D, which is still clottable). Fragment X is further degraded to nonclottable fragments Y (D-E) and D. Fragment Y can be digested into its constituent D and E fragments. Proteolysis of crosslinked fibrin by plasmin results in fragment DD (D-Dimer consisting of the D domains of 2 fibrin molecules crosslinked via the gamma chains), fragment E (central E domain) as well as DDE in which fragment E is noncovalently associated with DD. The molecular weights of the cleavage fragments produced from human crosslinked fibrin are: 184 kDa for fragment DD, 92 kDa for D, 50 kDa for E, 1.54 kDa for FpA and 1.57 kDa for FpB. Most of the fibrinogen in the circulation consists of 2 copies of each chain (Aalpha2, Bbeta2, gammaA2), but in normal plasma approximately 10% of the fibrinogen molecules contain one gammaA chain and one variant gamma chain (termed gamma'), in which the c-terminal AGDV residues are replaced with the amino acid sequence VRPEHPAETEYDSLYPEDDL. This variant fibrinogen is commonly referred to as fibrinogen gamma prime (gammaA/gamma') but has also been called fibrinogen 2 or peak 2 fibrinogen because it elutes separately from fibrinogen 1 (gammaA2) by ion exchange chromatography. Residues 414-427 of the gamma' chain of fibrin gamma prime (contain a high-affinity binding site for exosite II of thrombin, which allows the active site of bound thrombin to remain available to interact with substrates while demonstrating resistance to heparin mediated inhibition by antithrombin1-4.
Suitable as a source of peroxidase labeled antibodies to gamma'- containing forms of human fibrinogen.
1. Hantgan RR, Francis CW, Marder VJ; Fibrinogen Structure and Physiology; in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp 277-300, J.B. Lippincott Co., Philadelphia PA, USA, 1994.
2. Binnie CG, Lord ST; The Fibrinogen Sequences that Interact with Thrombin; Blood 81, pp 3186-3192, 1993.
3. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz JI; Evidence that both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin; JBC 278, pp 21584-21591, 2003.
4. Medved L, Weisel JW; Recommendations for Nomenclature on Fibrinogen and Fibrin; JTH 7, pp 355-359, 2009.

Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000